Related Experiment Video
Updated: Oct 23, 2025
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
Upregulation of miR181a/miR212 Improves Myogenic Commitment in Murine Fusion-Negative Rhabdomyosarcoma
Enrico Pozzo1,2, Nefele Giarratana1, Gabriele Sassi1
1Stem Cell Institute Leuven, KU Leuven, Leuven, Belgium.
Abstract:
Fusion-negative rhabdomyosarcoma (FN-RMS) is the most common soft tissue sarcoma of childhood arising from undifferentiated skeletal muscle cells from uncertain origin. Currently used therapies are poorly tumor-specific and fail to tackle the molecular machinery underlying the tumorigenicity and uncontrolled proliferation of FN-RMS. We and other groups recently found that microRNAs (miRNA) network contributes to myogenic epigenetic memory and can influence pluripotent stem cell commitments. Here, we used the previously identified promyogenic miRNAs and tailored it to the murine FN-RMS. Subsequently, we addressed the effects of miRNAs in vivo by performing syngeneic transplant of pre-treated FN-RMS cell line in C57Bl/6 mice. miRNA pre-treatment affects murine FN-RMS cell proliferation in vivo as showed by bioluminescence imaging analysis, resulting in better muscle performances as highlighted by treadmill exhaustion tests. In conclusion, in our study we identified a novel miRNA combination tackling the anti-myogenic features of FN-RMS by reducing proliferation and described novel antitumorigenic therapeutic targets that can be further explored for future pre-clinical applications.
Insights
Researchers identified a novel microRNA combination to treat fusion-negative rhabdomyosarcoma (FN-RMS). This microRNA therapy reduces tumor proliferation and improves muscle function in preclinical models, offering new therapeutic targets for childhood cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Fusion-negative rhabdomyosarcoma (FN-RMS) is a prevalent childhood soft tissue sarcoma with poorly specific therapies.
- Current treatments do not effectively address the molecular drivers of FN-RMS tumorigenicity and proliferation.
- MicroRNA (miRNA) networks are implicated in myogenic epigenetic memory and stem cell differentiation.
Purpose of the Study:
- To investigate the therapeutic potential of promyogenic miRNAs in murine FN-RMS.
- To evaluate the in vivo effects of tailored miRNA treatments on FN-RMS.
- To identify novel antitumorigenic targets for FN-RMS treatment.
Main Methods:
- Tailoring previously identified promyogenic miRNAs for murine FN-RMS.
- Performing syngeneic transplantation of miRNA-pre-treated FN-RMS cell lines in C57Bl/6 mice.
- Assessing tumor proliferation using bioluminescence imaging and muscle performance via treadmill exhaustion tests.
Main Results:
- miRNA pre-treatment significantly affected murine FN-RMS cell proliferation in vivo.
- Bioluminescence imaging demonstrated reduced tumor growth post-miRNA treatment.
- Treadmill exhaustion tests indicated improved muscle performance in treated mice.
Conclusions:
- A novel miRNA combination was identified that counteracts the anti-myogenic properties of FN-RMS.
- This miRNA therapy effectively reduces tumor proliferation and enhances muscle function.
- The study presents novel antitumorigenic targets for future preclinical development in FN-RMS therapy.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
09:21Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
